Technical Analysis for MRTX - Mirati Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
64.05 | -0.14% | -0.09 |
MRTX closed up 2.67 percent on Thursday, January 17, 2019, on 3.05 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical MRTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 17 | Pocket Pivot | Bullish Swing Setup | -0.14% |
| Jan 17 | Volume Surge | Other | -0.14% |
| Jan 17 | Calm After Storm | Range Contraction | -0.14% |
| Jan 17 | NR7 | Range Contraction | -0.14% |
| Jan 17 | Inside Day | Range Contraction | -0.14% |
| Jan 17 | Wide Bands | Range Expansion | -0.14% |
| Jan 17 | Overbought Stochastic | Strength | -0.14% |
| Jan 16 | Bearish Engulfing | Bearish | 2.53% |
| Jan 16 | Slingshot Bullish | Bullish Swing Setup | 2.53% |
| Jan 16 | New 52 Week High | Strength | 2.53% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-07
Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRTX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 67.13 |
| 52 Week Low | 24.65 |
| Average Volume | 632,174 |
| 200-Day Moving Average | 45.2082 |
| 50-Day Moving Average | 43.2322 |
| 20-Day Moving Average | 48.6685 |
| 10-Day Moving Average | 57.46 |
| Average True Range | 3.8416 |
| ADX | 38.99 |
| +DI | 38.9915 |
| -DI | 8.2467 |
| Chandelier Exit (Long, 3 ATRs ) | 55.6052 |
| Chandelier Exit (Short, 3 ATRs ) | 45.9148 |
| Upper Bollinger Band | 69.2626 |
| Lower Bollinger Band | 28.0744 |
| Percent B (%b) | 0.88 |
| BandWidth | 84.6301 |
| MACD Line | 6.3827 |
| MACD Signal Line | 4.4542 |
| MACD Histogram | 1.9285 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.6 Billion |
| Num Shares | 25 Million |
| EPS | -3.38 |
| Price-to-Earnings (P/E) Ratio | -18.98 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 3.81 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 67.82 | ||||
| Resistance 3 (R3) | 67.83 | 66.61 | 67.20 | ||
| Resistance 2 (R2) | 66.61 | 65.68 | 66.61 | 67.00 | |
| Resistance 1 (R1) | 65.38 | 65.10 | 66.00 | 65.37 | 66.79 |
| Pivot Point | 64.16 | 64.16 | 64.47 | 64.16 | 64.16 |
| Support 1 (S1) | 62.93 | 63.23 | 63.55 | 62.92 | 61.49 |
| Support 2 (S2) | 61.71 | 62.65 | 61.71 | 61.28 | |
| Support 3 (S3) | 60.48 | 61.71 | 61.08 | ||
| Support 4 (S4) | 60.47 |
